# EDGAR Filing Document

**Accession Number:** 0001355736
**File Stem:** 0001493152-23-001224
**Filing Date:** 2023-1
**Character Count:** 18482
**Document Hash:** e32b7379ed67453b482bd0d221581550
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-001224.hdr.sgml**: 20230112

**ACCESSION NUMBER**: 0001493152-23-001224

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20221031

**FILED AS OF DATE**: 20230112

**DATE AS OF CHANGE**: 20230112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Avricore Health Inc.
- **CENTRAL INDEX KEY:** 0001355736
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51848
- **FILM NUMBER:** 23524857

**BUSINESS ADDRESS:**
- **STREET 1:** 789 WEST PENDER STREET
- **STREET 2:** SUITE 810
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 1H2
- **BUSINESS PHONE:** 604-687-2038

**MAIL ADDRESS:**
- **STREET 1:** 789 WEST PENDER STREET
- **STREET 2:** SUITE 810
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 1H2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vanc Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20140911

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NUVA Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20140110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALDA Pharmaceuticals Corp.
- **DATE OF NAME CHANGE:** 20060309

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October, 2022.

Commission File Number: **000-51848**

Avricore Health Inc.

(Exact name of registrant as specified in its charter)

1120-789 West Pender St, Vancouver, BC, V6C 1H2

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u>NO</u>

**Note**: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u>NO</u>

**Note**: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Exhibits

The following exhibits are included in this form 6-K:

---

| | | |
|:---|:---|:---|
| Exhibit No. | Description | Date Released |
| 1 | [News Release- HEALTHTAB<sup>TM</sup> ROLL OUT ON TRACK AND OPERATIONS CASHFLOW POSITIVE](ex-1.htm)<br>| October 11, 2022 |
| 2 | [News Release- AVRICORE TO PRESENT AT EMERGING GROWTH CONFERENCE ON OCT. 26, 2022](ex-2.htm)<br>| October 21, 2022 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AVRICORE HEALTH INC.** | **AVRICORE HEALTH INC.** |
| Date: January 11, 2023 | By | *"Kiki Smith"* |
|  |  | Kiki Smith |
|  |  | Chief Financial Officer |

---

## Ex-1

**Exhibit 1**

**HEALTHTAB<sup>TM</sup> ROLL OUT ON TRACK AND OPERATIONS CASHFLOW POSITIVE**

VANCOUVER, BRITISH COLUMBIA – October 11, 2022) – **AVRICORE HEALTH INC.** (TSXV: AVCR) (the "**Company**" or "**AVCR**") is pleased to provide this corporate update on the Company's execution expanding its powerful chronic-disease screening and reporting platform, HealthTab.

On August 8<sup>th</sup>, the Company announced a new Master Service Agreement and Statement of Work was signed with Shoppers Drug Mart pharmacies to significantly expand the HealthTab point-of-care testing platform to up to 450 locations nation-wide, with affiliated locations under the Loblaw family of brands being included.

"The team has been exceptional in deploying systems and we have already deployed more than half of the target locations," said Hector Bremner, Avricore Health's CEO. "We are on track to achieve the late-November target for full deployment."

Once a pharmacy has HealthTab onsite there is a period of training and acclimating teams with the workflow. Nevertheless, data from locations is indicating strong utilization and patient uptake, generating strong consumables-based revenues.

In fact, HealthTab already has positive cash-flow from operations and is expected to significantly ramp up gross revenues over the next 12 months yielding target margins and profitability by Q2 2023.

Supporting the optimism of strong and sustainable growth are the anticipated policy and funding announcements related to point-of-care in community pharmacy by the federal and provincial governments in the coming weeks and months. These changes and commitments will have a significant impact on sales volumes in 2023, not to mention demand from pharmacy groups to install HealthTab.

For example, on October 5<sup>th</sup>, the Government of Canada tabled its Framework for Diabetes in Canada, which lays out an aggressive strategy to better screen, surveil, prevent, and manage this disease which currently costs $30 Billion CAD annually to treat. To find the details, please visit:

<u>https://www.canada.ca/en/public-health/services/publications/diseases-conditions/framework-diabetes-canada.html</u>

Also, in addition to Alberta and Ontario, British Columbia recently announced their plan to expand the scope of pharmacy practice, which includes limited prescribing as of October 14<sup>th</sup>, and makes further commitments to work with the profession to identify additional ways they can contribute to healthcare solutions, such as chronic disease screening and support, as in other jurisdictions. To learn more, please visit: <u>https://news.gov.bc.ca/releases/2022HLTH0059-001464</u>

Internationally, policy and funding supporting more scope for pharmacist to tackle chronic disease and alleviate the pressures being faced for primary care also give a great deal of confidence that HealthTab's objective of being the world's leading point-of-care solution for pharmaciast has a bright future. The coming weeks and months are expected to bring positive news and new opportunities for our current EU, UK and US program initiatives.

**HealthTab™ Market Fast Facts**

● Point of Care Testing Market to reach $93.21 Billion USD in 2030 (<u>Source</u>)

● Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (<u>Source</u>)

● Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (<u>Source</u>)

![](ex1_001.jpg)

● Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (<u>Source</u>)

● There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

**About HealthTab™**

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

**About Avricore Health Inc.**

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

**Contact**:

**Avricore Health Inc.**

Hector Bremner, CEO 604-773-8943

<u>info@avricorehealth.com</u>

<u>www.avricorehealth.com</u>

**Cautionary Note Regarding Forward-Looking Statements**

Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release.

Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

 

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy*

## Ex-2

**Exhibit 2**

**AVRICORE TO PRESENT AT EMERGING GROWTH CONFERENCE ON OCT. 26, 2022**

VANCOUVER, BRITISH COLUMBIA – October 21, 2022 – **AVRICORE HEALTH INC.** (TSXV: AVCR) (the "**Company**" or "**AVCR**") is excited to present at the Emerging Growth Conference on October 26<sup>th</sup>.

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Hector Bremner in real time on the Company's current activities. After a short presentation, the floor will be subsequently opened for questions, where Mr. Bremner will do his best to get through as many of them as possible.

**Call Details:**

October 26, 2022 @ 11:30am PT / 2:30pm ET

Please register here to ensure you can attend the conference and receive any updates that are released: <u>https://goto.webcasts.com/starthere.jsp?ei=1575084&tp_key=b452034330&sti=avcrf</u>

*\*If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on www.EmergingGrowth.com and we will also release a link to that after the event*.

**Agenda:**

The 30-minute call agenda will be as follows:

15Min: Overview Presentation

15Min: Q&A

We're looking forward to seeing you there, please review our most recent investor presentation

here: <u>www.avricore.com</u>

**About the Emerging Growth Conference**

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

**About HealthTab™**

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

![](ex2_002.jpg)

**HealthTab™ Market Fast Facts**

● Point of Care Testing Market to reach $93.21 Billion USD in 2030 (<u>Source</u>)

● Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (<u>Source</u>)

● Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (<u>Source</u>)

● Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed (<u>Source</u>)

● There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

**About Avricore Health Inc.**

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

**Contact**:

**Avricore Health Inc.**

Hector Bremner, CEO 604-773-8943

<u>info@avricorehealth.com</u>

<u>www.avricorehealth.com</u>

**Cautionary Note Regarding Forward-Looking Statements:**

Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

 

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.*